Related Experiment Video
Updated: Apr 30, 2026
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
End-stage valvular heart disease requiring heart transplantation: risk profile, surgical modifiers, and myocardial
Yifan Wang1,2,3, Yiqi Zhao1,2,3, Weiteng Wang2,3
1Beijing Key Laboratory of Xenotransplantation, Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Insights
Timely cardiac valvular surgery (CVS) before significant heart failure in valvular heart disease (VHD) patients may prolong the time to heart transplant (HTx). Prosthetic valve function is often preserved at transplant, indicating advanced myocardial disease as the primary cause of heart failure.
Area of Science:
- Cardiology
- Transplantation Medicine
- Cardiac Surgery
Background:
- End-stage valvular heart disease (VHD) is a high-risk condition for heart transplant (HTx) recipients.
- Limited data exist on the natural history and progression factors for VHD patients requiring HTx.
Purpose of the Study:
- To characterize the clinical, genetic, surgical, and pathological factors in patients undergoing HTx for end-stage VHD.
- To determine if timely cardiac valvular surgery (CVS) can mitigate progression to end-stage heart failure.
Main Methods:
- Retrospective analysis of 961 HTx recipients (2012-2023).
- Identification of 45 patients with non-ischemic VHD due to primary aortic valve lesions using echocardiography, cardiac MRI, and explant pathology.
- Exclusion of ischemic and non-valvular cardiomyopathies.
Main Results:
- 78% of patients had prior CVS; earlier CVS correlated with longer intervals to HTx.
- Genetic variants were linked to earlier onset but not faster progression to HTx.
- Prosthetic valves were preserved in 77% of explanted hearts, suggesting myocardial disease, not prosthetic failure, caused terminal heart failure.
Conclusions:
- Valve intervention before major decompensation in VHD patients is associated with longer pre-HTx intervals.
- Terminal heart failure in this cohort often stems from advanced myocardial remodeling rather than prosthetic valve failure.
Background:
End-stage valvular heart disease (VHD) constitutes a small but high-risk subset of heart transplant (HTx) recipients, and data describing their natural history and determinants of progression to HTx are limited. We aimed to characterize the clinical, genetic, surgical, and pathological substrates of patients undergoing HTx for end-stage VHD and to assess whether timely cardiac valvular surgery (CVS) mitigates progression to end-stage heart failure.
Methods:
We retrospectively screened 961 consecutive recipients who underwent HTx for end-stage heart failure between January 2012 and December 2023. Patients with non-ischemic end-stage VHD due to a primary aortic valve lesion were identified by echocardiography and further adjudicated using cardiac magnetic resonance and explant pathology. After excluding ischemic and non-valvular cardiomyopathies and other predefined conditions, 45 patients constituted the final cohort.
Results:
Of the 45 recipients, 78% had undergone prior CVS. CVS performed before heart failure or malignant ventricular arrhythmia was associated with a longer interval from symptom onset to HTx. In contrast, genetic variants were associated with earlier disease onset but did not significantly shorten the progression interval to HTx. Among 27 patients with prosthetic valves, 22 (77%) had structurally and hemodynamically preserved prostheses at the time of HTx, indicating that terminal HF predominantly reflected advanced myocardial disease rather than prosthetic failure. Explanted hearts consistently demonstrated extensive replacement fibrosis, and patients with malignant ventricular arrhythmias exhibited more prominent adipose replacement.
Conclusions:
Among patients transplanted for end-stage VHD, valve intervention performed prior to major clinical decompensation was associated with longer time intervals to HTx within this transplanted cohort. Most prosthetic valves showed preserved function at the time of HTx, supporting the concept that terminal heart failure in this setting often reflects advanced myocardial remodeling rather than prosthetic valve failure.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:26Mitral Stenosis III: Medical Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:28Kidney Transplant I: Introduction